Enzymatic Degradation

Key Peptide-Degrading Enzymes

Exopeptidases (Terminal Cleavage)

Enzyme	Target	Location	Peptides Affected
DPP-4	N-terminal X-Pro or X-Ala	Blood, tissues	GLP-1, GIP, many peptides
Aminopeptidases	N-terminus	Widespread	Most peptides
Carboxypeptidases	C-terminus	Blood, tissues	Most peptides
ACE	C-terminal dipeptide	Lung, blood	Angiotensin, bradykinin

Endopeptidases (Internal Cleavage)

Enzyme	Specificity	Location	Substrates
Neprilysin (NEP)	Hydrophobic residues	Kidney, brain	ANP, BNP, substance P
Trypsin	Lys-X, Arg-X	GI tract	Dietary peptides
Chymotrypsin	Phe-X, Tyr-X, Trp-X	GI tract	Dietary peptides
Elastase	Ala-X, Val-X	GI tract, neutrophils	Various
Matrix metalloproteinases	Various	Tissues	ECM peptides

Half-Lives of Native Peptides

Peptide	Native Half-Life	Primary Enzyme	Modified Version Half-Life
GLP-1	1-2 minutes	DPP-4	Semaglutide: ~7 days
GIP	5-7 minutes	DPP-4	Modified GIP: hours-days
Insulin	5-6 minutes	Insulinase	Glargine: ~24 hours
Glucagon	3-6 minutes	DPP-4, proteases	Modified: hours
ANP	3 minutes	NEP	Sacubitril combo: hours
Oxytocin	3-5 minutes	Oxytocinase	Carbetocin: 4-10x longer

Degradation in Different Compartments

Gastrointestinal Tract

Barrier	Enzymes Present	Challenge
Stomach	Pepsin, HCl	Acid hydrolysis
Duodenum	Trypsin, chymotrypsin	Major proteolysis
Jejunum/ileum	Brush border peptidases	Final breakdown
Intestinal wall	Cytoplasmic peptidases	During absorption

This is why most peptides cannot be taken orally.

Blood/Plasma

Enzyme Class	Examples	Activity
Serine proteases	Thrombin, plasmin	Coagulation-related
DPP family	DPP-4, FAP	N-terminal trimming
ACE	ACE, ACE2	C-terminal cleavage
Carboxypeptidases	CPN, CPB	C-terminal removal

Tissue/Cellular

Location	Key Enzymes	Function
Cell surface	NEP, ACE, DPP-4	Extracellular clearance
Lysosomes	Cathepsins	Intracellular degradation
Endosomes	Cathepsins	Receptor-bound peptide
Cytoplasm	Various peptidases	Cytoplasmic peptides

Strategies to Resist Enzymatic Degradation

Amino Acid Modifications

Strategy	Mechanism	Example
D-amino acids	Enzymes don’t recognize	D-Ala at DPP-4 site
N-methylation	Blocks enzyme access	NMe-amino acids
Alpha-methylation	Steric hindrance	Aib (aminoisobutyric acid)
Unnatural amino acids	Not recognized	Semaglutide: Aib at position 8
Beta-amino acids	Altered backbone	Peptide mimetics

Structural Modifications

Strategy	Mechanism	Application
Cyclization	Removes termini	Cyclosporine, octreotide
Disulfide stapling	Constrains structure	Somatostatin analogs
N-terminal acetylation	Blocks aminopeptidases	Many research peptides
C-terminal amidation	Blocks carboxypeptidases	Most therapeutic peptides
PEGylation	Steric shielding	Pegfilgrastim

Carrier Approaches

Strategy	Mechanism	Example
Albumin binding	Sequestration, size	Semaglutide (fatty acid)
Fc fusion	Size, recycling	Dulaglutide
Albumin fusion	Size, long circulation	Albiglutide
Lipidation	Albumin binding	Liraglutide, semaglutide

Case Study: GLP-1 Agonists

Evolution of DPP-4 resistance:

Drug	Half-Life	Strategy Used
Native GLP-1	2 min	None
Exenatide	2.4 hours	Exendin sequence (DPP-4 resistant)
Liraglutide	13 hours	Aib8 + fatty acid (albumin binding)
Semaglutide	7 days	Aib8 + C18 fatty acid (stronger binding)
Tirzepatide	5 days	Aib2 + C20 fatty acid

Predicting Susceptibility

Sequence Analysis Tools

Tool/Method	Purpose
PeptideCutter	Predict protease cleavage sites
MEROPS database	Protease specificity information
In silico modeling	Predict vulnerable positions

High-Risk Motifs

Motif	Susceptible To	Solution
X-Pro N-terminus	DPP-4	Substitute or protect
Lys-X or Arg-X	Trypsin-like	Substitute
Phe-X, Tyr-X	Chymotrypsin-like	Substitute
Unprotected termini	Exopeptidases	Cap termini

Frequently Asked Questions

Why do peptide drugs need modifications to work?

Native peptides evolved for rapid signaling with quick on/off kinetics. For drugs, we need sustained activity. Without modifications, most peptides are degraded within minutes, requiring impractical dosing (continuous infusion). Modifications extend half-life from minutes to hours or days.

Can enzymatic degradation be completely prevented?

Not entirely, but it can be dramatically slowed. Even the longest-acting peptides (semaglutide at 7 days) are eventually degraded. The goal is achieving a therapeutically useful half-life, not infinite stability. Complete resistance would also prevent eventual clearance.

How do D-amino acids provide protection?

Most proteases evolved to recognize L-amino acids (the natural form). D-amino acids are mirror images that don’t fit the enzyme’s active site. Incorporating even one D-amino acid at a cleavage site can provide substantial protection from that specific enzyme.